The present invention relates to the field of prodrugs of chemotherapeutic agents and method of use thereof.
U.S. Pat. No. 4,786,495 to Bird discloses flurbiprofen and salts thereof in admixture with an excipient encompassing fatty acid esters such as polyol esters of polyethylene glycol.
U.S. Pat. No. 5,681,964 to Ashton relates to soluble ester prodrugs of polyethylene glycol and various chemotherapeutic agents.
U.S. Pat. No. 4,767,751 to David discloses polyethylene glycol type solubilizers for flurbiprofen U.S. Pat. No. 4,613,505 to Mizushima discloses esters of flurbiprofen which may be dissolved in a vegetable oil and emulsified.
U.S. Pat. Nos. 4,489,080 and 4,443,476 to Lomen discloses alkyl esters of flurbiprofen.
U.S. Pat. No. 4,477,468 to Heckler discloses the systemic administration and topical application of flurbiprofen, salts thereof and esters thereof. The esters are (C1–C8) alkyl esters and are prescribed for the prophylactic and therapeutic treatment of herpes type II virus. U.S. Pat. Nos. 4,473,584, 4,443,476 and 4,439,451 are related to U.S. Pat. No. 4,477,468.
U.S. Pat. No. 4,412,994 to Sloan discloses hydroxamic derivatives of flurbiprofen as prodrugs
U.S. Pat. No. 4,206,220 relates to compounds that are similar to those of U.S. Pat. No. 4,412,994. These compounds are aminoxy derivatives of, e.g., flurbiprofen.
U.S. Pat. No. 4,009,283 to Herr et al discloses lower alkyl esters of flurbiprofen. The esters are lower alkyl esters.
Canadian Patent CA 1,148,165 and German Patent DE 3,811,118 disclose esters of flurbiprofen.
The anti-inflammatory agent, flurbiprofen, produces local irritation when applied for treatment of inflammation. Various techniques have been used to lower the dosage of flurbiprofen to the patient, such as techniques for rapid release of flurbiprofen into the body. Nevertheless, there exists a need in the art for compositions that achieve the desired effects of flurbiprofen without the concomittant local irritation. This is particularly true in the application of the flurbiprofen anti-inflammatory agent to the eye.
An advantage of the present invention is to provide covalent conjugates of chemotherapeutic agents with mono- di- and polyoxaalkanoic or thiaalkanoic acids.
A further advantage of the present invention is the ability to adjust the solubility of steroidal molecules, lipophilicity and their half-life in the body and thus, bioavailability, by altering the structure and length of the oxaalkanoic acid or polyoxaalkanoic acid chain.
A further advantage of the present invention is to provide compounds having a chemotherapeutic effect which avoids or reduces the local irritation brought about by administration of the parent drug.
Another advantage of the present invention is to provide a pharmaceutical composition comprising a compound having a chemotherapeutic effect, but a reduced local irritation as compared to that produced by the parent drug.
Yet another advantage of the present invention is the ability of the prodrugs to permeate biological membranes, for example, the stratum corneum, and remain there until enzymatically cleaved, can be enhanced.
Additional advantages of the present invention will be set forth in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from the practice of the present invention. The objects and advantages of the invention may be realized and obtained as particularly pointed out in the appended claims.
According to the present invention, the foregoing and other advantages are achieved in part by providing a prodrug composition comprising a chemotherapeutic agent linked to a variety of oxaalkanoic acids of the formulas shown in Structures 1 and 2 wherein n=1–12. In a preferred embodiment n=1–6.
Additional advantages of the present invention will become readily apparent to those skilled in this art from the following detailed description, wherein embodiments of the present invention are described simply by way of illustrating of the best mode contemplated in carrying out the present invention. As will be realized, the present invention is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the present invention. Accordingly, the drawings and description are to be regarded as illustrative in nature and not as restrictive.
The present invention relates to soluble ester and amide prodrugs of various alkanoic acids, such as , oxaalkanoic acids, including thiaalkanoic acids, oxahydroxyalkanoic acids, oxaalkoxyalkanoic acids, oxadialkanoic acids, and oxaaminoalkanoic acids covalently linked to a chemotherapeutic agent.
Examples of chemotherapeutic agents, include, but are not limited to triamcinolone acetonide, AZT, DDI, DDC, acyclovir, ritonavir, saquinavir, gancyclovir, 5-fluorouracil, camptothecin, isoniazid, and timolol.
In accordance with this invention, provided are formulas 1 and 2 of the structural moieties that are covalently linked to the drug molecule to form the prodrug.
Formula 1 is
wherein X=0 or S; R1═OH, OR8 (R8 is C1–C4 alkyl, C3–C4 branched alkyl, C3–C4 cycloalkyl), O—CH2—COOH, NHR9 (R9 is H, C1–C4 alkyl, C3–C4 branched alkyl, C3–C4 cycloalkyl), +NH2R9Z− (Z− is Cl−, Br−, HSO4−, SO42−, NO3−, HClO4−, I−, H2PO42−PO43− and other pharmaceutically acceptable salt anions, including anions of pharmaceutically acceptable organic acids and organic diacids.
Pharmaceutically acceptable organic acids and organic diacids, include, for example, tartrate, maleate, fumarate, pivalate, mesylate, citrate, tosylate, ascorbate, mucate, acetate, benzoate, salicylate, and succinate.
R2, R3, R4, R5, R6, and R7 are selected from the group consisting of H, C1–C4 alkyl, C1–C4 hydroxyalkyl; and n is a number from 1 to 12.
Formula 2 is
wherein X is O or S, R1 is COOH, CO2R6(R6 is C1–C4 alkyl, C3–C4 branched alkyl, C3–C4 cycloalkyl); R2, R3, R4, and R5 are selected from a group consisting of H, C1–C4 alkyl, C1–C4 hydroxyalkyl.
Formulas 3 to 6 show the functionality on the drug molecule that is conjugated to alkanoic acid described in structures 1 and 2.
DRUG-C(═O)—OH 3
DRUG-X—H X═O or S 4
DRUG-NHR R═H or an N-substituent in the drugmolecule 5
DRUG-C(═O)—NHR R═H or an N-substituent in the drug molecule 6
The present invention provides drug conjugating moieties of the formula:
wherein Y is O, S, NR8 (R8 is H or C1–C4 alkyl, C3–C4 branched alkyl, or C3–C4 cycloalkyl); X is O or S; R1 is OH, OR9 (R9 is C1–C4 alkyl, C3–C4 branched alkyl, and C3–C4 cycloalkyl), O—CH2—COOH, NH2 or +NH3Z− (Z− is Cl−, Br−, HSO4−, SO4−, NO3−, HClO4−, I−, H2PO4−, HPO4−, HPO42−, PO43− and other pharmaceutically acceptable salt anions, including anions of pharmaceutically acceptable organic acids and diacids, including but not restricted to tartrate, maleate, pivalate, fumarate, mesylate, citrate, tosylate, ascorbate, mucate, acetate, benzoate, salicylate, and succinate); R2 to R7 are selected from the group consisting of H, C1–C4 alkyl, C1–C4 hydroxyalkyl; and n is a number from 1 to 12.
The present invention also provides drug conjugating moieties of the formula:
wherein Y is O, S, NR8 (R8 is H, or C1–C4 alkyl, C3–C4 branched alkyl, C3–C4 cycloalkyl); X is O or S; R1 is H or C1–C4 alkyl, C3–C4 branched alkyl, or C3–C4 cycloalkyl; R2 to R7 are selected from the group consisting of H, C1–C4 alkyl, C1–C4 hydroxyalkyl; and n is a number from 1 to 12.
The present invention further provides drug conjugating moieties of the formula:
wherein X is O or S; Z is O, S, NR6 (R6 is H, C1–C4 alkyl, C3–C4 branched alkyl, C3–C4 cycloalkyl); R1 is H, or C1–C4 alkyl, C3–C4 branched alkyl, or C3–C4 cycloalkyl; R2 to R5 are selected from the group consisting of H, C1–C4 alkyl, C1–C4 hydroxyalkyl.
The present invention includes alkali metal and alkali earth salts of drug conjugate 7, 8, and 9 when a free carboxylic acid moiety is present in the molecule.
Preferred compounds according to formula 7 are those wherein X═O, R1 is OH, OR9 (R9═C1–C4 alkyl), OCH2COOH, NH2, and R2, R3, R4, R5, R6, R7 are hydrogen and n is a number from 1 to 6. Even more preferred are compounds according to formula 7 are those wherein R2, R3, R4, R5, R6 and R7 are hydrogen and n is 2, 4 or 6 and R1 is OH, OR9 (R9═CH3), OCH2COOH.
Preferred compounds according to formula 8 are those wherein Y═O, NR8 (R8 is H or C1–C4 alkyl), X=0, and wherein R1 is H or C1–C4, and R2, R3, R4, R5, R6, and R7 are hydrogen, and n is 2, 4, or 6.
Preferred compounds according to formula 9 are those wherein X is O, Z is O or NR6 (R6 is H or C1–C4 alkyl), R1 is H or C1–C4 alkyl, and R2, R3, R4 and R5 are H.
It should be appreciated that the compounds illustrated in formulas 7–9 may have one or more asymmetric carbon atoms and may exist as optical and/or diastereomeric isomers. For the purpose of this invention the racemic mixtures and dextro and levo forms, and all diastereomeric forms, are included within the present invention. The racemic mixtures are preferred.
Further, the compounds of the present invention are useful in pharmaceutical compositions for systemic administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, suppositories, sterile parenteral solutions or suspensions, sterile non-parenteral solutions or suspensions oral solutions or suspensions, oil in water or water in oil emulsions and the like, containing suitable quantities of an active ingredient. Topical application can be in the form of ointments, creams, lotions, jellies, sprays, douches, and the like. For oral administration either solid or fluid unit dosage forms can be prepared with the compounds of Formulas 7–9. The compounds are useful in pharmaceutical compositions (wt %) of the active ingredient with a carrier or vehicle in the composition range 1–99%.
Either fluid or solid unit dosage forms can be readily prepared for oral administration. For example, the compounds of Formulas 7–9 can be mixed with conventional ingredients such as dicalcium phosphate, magnesium aluminum silicate, magnesium stearate, calcium sulfate, starch, talc, lactose, acacia, methyl cellulose and functionally similar materials as pharmaceutical excipients or carriers. A sustained release formulation may optionally be used. Capsules may be formulated by mixing the compound with a pharmaceutical diluent which is inert and inserting this mixture into a hard gelatin capsule having the appropriate size. If soft capsules are desired a slurry of the compound with an acceptable vegetable, light petroleum, or other inert oil can be encapsulated by machine into a gelatin capsule.
Suspensions, syrups and elixirs may be used for oral administration of fluid unit dosage forms. A fluid preparation including oil may be used for oil soluble forms. A vegetable oil such as corn oil, peanut oil or safflower oil, for example, together with flavoring agents, sweeteners and any preservatives produces an acceptable fluid preparation. A surfactant may be added to water to form syrup for fluid unit dosages. Hydroalcoholic pharmaceutical preparations may be used having an acceptable sweetener such as sugar, saccharin or biological sweetener and a flavoring agent in the form of an elixir.
Pharmaceutical compositions for parenteral and suppository administration can also be obtained using techniques standard in the art.
Another use of the compounds according to the invention is as a topical agent, as appropriate, suitable for application to either the eyes, ears, or skin. Another additional use of the compounds is in a transdermal, parenteral pharmaceutical preparation, which in some examples may be particularly useful in the treatment of inflamed connective tissue in a mammal such as a human.
Accordingly, compositions suitable for administration to these areas are particularly included within the invention. The above parenteral solutions or suspensions may be administered transdermally and, if desired a more concentrated slow release form may be administered. Accordingly, incorporation of the active compounds in a slow release matrix may be implemented for administering transdermally. The compounds may be administered transdermally at about 1 to 20% of the composition and preferably about 5 to 15% wt % of the active ingredient in the vehicle or carrier.
Transdermal therapeutic systems are self-contained dosage forms that, when applied to intact skin, deliver drug(s) at a controlled rate to the systemic circulation. Advantages of using the transdermal routing include: enhanced therapeutic efficacy, reduction in the frequency of dosing, reduction of side effects due to optimization of the blood-concentration versus time profile, increased patient compliance due to elimination of multiple dosing schedules, bypassing the hepatic “first-pass” metabolism, avoiding gastrointestinal incompatibilities and providing a predicable and extended duration of activity. However, the main function of the skin is to act as a barrier to entering compounds. As a consequence, transdermal therapy has so far been restricted to a limited number of drugs that possess the desirable physicochemical properties for diffusion across the skin barrier. One effective method of overcoming the barrier function of the skin is to include a penetration enhancer in the formulation of a transdermal therapeutic system. See Barry, Brian W.: Dermatological Formulations: Percutaneous Absorption (Dekker, New York, 1983); Bronough et al, Percutaneous Absorption, Mechanisms-Methodology-Drug Delivery, (Marcel Dekker, New York, N.Y. 1985); and Monkhouse et al, Transdermal drug deliver-problems and promises. Drug Dev. Ind. Pharm., 14, 183–209 (1988).
Thus, a penetration enhancer may also be included in the prodrug formulation, which may be of the type described below. Several different types of penetration enhancers have been reported such as dimethylsulfoxide, n-decyl methyl sulfoxide, N,N-dimethylacetamide, N,Ni-dimethylformamide, 1-dodecylazacycloheptan-2-one (Azone), propylene glycol, ethanol, pyrrolidones such as N-methyl-2-pyrrolidone (NMP) and surfactants. See Bronough et al, supra, and Stoughton et al, Azone: a New Non-toxic enhancer of percutaneous penetration. Drug Dev. Inc. Pharm., 9, 725–744 (1983).
N-methyl-2-pyrrolidone is a versatile solvent which is miscible with water, ethyl alcohol, ether, chloroform, benzene, ethyl acetate and carbon disulfide. N-methyl-2-pyrrolidone has been widely used as a solvent in industrial processes such as petroleum refining, GAF Corp.: “M-Pyrol (N-methyl-2-pyrrolidone) Handbook.”, GAF Corp., New York, 1972. It is currently used as a solubilizing agent in topical and parenteral veterinary pharmaceutical and is now under consideration for use in products intended for humans, Wells, D. A. et al: Disposition and Metabolism of Double-Labeled [3H and 14C] N-methyl-2-pyrrolidone in the Rat. Drug Met. Disps., 16, 243–249 (1988). Animal and human experiments have shown very little irritation or sensitization potential. Ames type assays and chronic exposure studies have not revealed any significant toxicity, Wells et al, Mutagenicity and Cytotoxicity of N-methyl-2-pyrrolidone and 4-(methyl amino) Butanoic Acid in the Salmonella/microsome Assay. J. Appl. Tox., 8, 135–139 (1988). N-methyl-2-pyrrolidone has also been shown to be an effective penetration enhancer. Barry et al, Optimization an Bioavailability of Topical Steroids: Penetration Enhancers Under Occlusion. J. Inv. Derm., 82, 49–52 (1984); Akter et al, Absorption Through Human Skin of Ibuprofen and Flurbiprofen; Effect of Dos Variation, Deposited Drug Films, Occlusion and Penetration Enhancer N-methyl-2-pyrrolidone. J. Pharm. Pharmacol., 37, 27–37 (1984); Holegaard et al, Vesical Effect on Topical Drug Delivery IV. Effect of N-methyl-2-pyrrolidone and Polar Lipids on Percutaneous Transport. Int. J. Pharm., 43, 233–240 (1988); Sugibayashi et al, Effect of Several Penetration Enhancers on the Percutaneous Absorption of Indomethacin in Hairless Rat. Chem. Pharm. Bull., 36, 1519–1529 (1988); Bennett et al, Optimization of Bioavailability of Topical Steroids: Non-occluded Penetration Enhancers Under Thermodynamic Control. J. Pharm. Pharmacol., 37, 298–304 (1985); Sasaki et al, Enhancing Effect of Pyrrolidone Derivatives on Transdermal Drug Delivery. 1. Int. J. Pharm., 44, 14–24 (1988); Lee et al, Toxicity of N-methyl-2-pyrrolidone (NMP): Teratogenic, Subchronic and Two-year Inhalation Studies, Fund. Appl., Tox., 9 222–235 (1987).
Compounds of formulas 7–9 can be present in the reservoir alone or in combination form with pharmaceutical carriers. The pharmaceutical carriers acceptable for the purpose of this invention are the art known carriers that do not adversely affect the drug, the host, or the material comprising the drug delivery device. Suitably pharmaceutical carriers include sterile water; saline, dextrose; dextrose in water or saline; condensation products of castor oil and ethylene oxide combining about 30 to 35 moles of ethylene oxide per mole of castor oil; liquid acid; lower alkanols; oils such as corn oil; peanut oil, sesame oil and the like, with emulsifiers such as mono- or di-glyceride of a fatty acid, or phosphatide, e.g., lecithin, and the like; glycols; polyalkylene glycols; aqueous media in the presence of a suspending agent, for example, sodium carboxymethylcellulose; sodium alginate; poly(vinylpyrrolidone); and the like, alone or with suitable dispensing agents such as lecithin; polyoxyethylene stearate; and the like. The carrier may also contain adjutants such as preserving, stabilizing, wetting, or emulsifying agents and the like together with the previously described penetration enhancers of this invention.
The effective dosage for mammals may vary due to such factors as age, weight activity level or condition of the subject being treated. Typically, an effective dosage of a compound according to the present invention is in the range 1 to 500 mg when administered by either oral or rectal dose from 1 to 3 time daily. This is about 0.02 to about 35 mg per kilogram of the subject's weight administered per day. Preferably about 5 to about 175 mg are administered orally or rectally 1 to 3 times a day for an adult human. The required dose is considerably less when administered parenterally, preferably about 1 to 15 mg may be administered intramuscularly or transdermally, 1 or 2 times a day for an adult human.
Compounds of the present invention may be administered topically at about 1 to 20% of the composition, and preferably about 5 to 15 wt %.
The compounds of the invention can be prepared by conventional esterification or acylation procedures known to those skilled in the art. For example, triamcinolone acetonide can be reacted with an appropriate oxaalkanoic acid chloride in the presence of base to produce the final product ester, according to the present invention.
The following non-limiting examples are given by way of illustration only.
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
1H NMR (CDCl3) δ 1.00 (t, 3H, 19-CH3), 2.20 (m, 2H, 18-CH2), 3.74 (s, 3H, OCH3), 4.26 (m, 2H, OCH2), 4.45 (d, 2H, OCH2), 5.26 (s, 2H, 5-CH2), 5.56 (dd, 2H, 17-CH2), 7.20 (s, 1H, 14-CH), 7.65 (t, 1H), 7.82 (t, 1H), 7.94 (d, 1H), 8.21 (d, 1H), 8.42 (s, 1H, 7-CH).
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
The reaction scheme is illustrated in
Specific compounds according to the present invention, together with some half-life data of hydrolysis of the prodrugs in human serum and phosphate buffer at pJ 7.4 is shown in Table 1.
In the previous descriptions, numerous specific details are set forth, such as specific materials, structures, chemicals, processes, etc., in order to provide a better understanding of the present invention. However, the present invention can be practiced without resorting to the details specifically set forth. In other instances, well-known processing structures have not been described in detail in order not to unnecessarily obscure the present invention.
Only the preferred embodiment of the invention and but a few examples of its versatility are shown and described in the present disclosure. It is to be understood that the present invention is capable of use in various other combinations and environments and is capable of changes or modifications within the scope of the inventive concept as expressed herein. All patents, patent applications and publication cited herein are incorporated by reference in their entirety.
This application is a divisional of application Ser. No. 09/565,079, filed May 4, 2000, now U.S. Pat. No. 6,765,019, which claims benefit of application 60/132,803, filed May 6, 1999.
Number | Name | Date | Kind |
---|---|---|---|
4009283 | Herr et al. | Feb 1977 | A |
4053638 | Litchfield et al. | Oct 1977 | A |
4083974 | Turi | Apr 1978 | A |
4206220 | Sloan | Jun 1980 | A |
4412994 | Sloan | Nov 1983 | A |
4439451 | Coleman | Mar 1984 | A |
4443476 | Lomen | Apr 1984 | A |
4473584 | Heckler | Sep 1984 | A |
4477468 | Heckler | Oct 1984 | A |
4489080 | Lomen | Dec 1984 | A |
4613505 | Mizushima et al. | Sep 1986 | A |
4767751 | Davis | Aug 1988 | A |
4786495 | Bird et al. | Nov 1988 | A |
4897417 | Patil et al. | Jan 1990 | A |
4935508 | Kamachi et al. | Jun 1990 | A |
4937253 | Gleason et al. | Jun 1990 | A |
4990499 | Gupta et al. | Feb 1991 | A |
5196438 | Martin et al. | Mar 1993 | A |
5482965 | Rajadhyaksha | Jan 1996 | A |
5501863 | Rossling et al. | Mar 1996 | A |
5578637 | Lai et al. | Nov 1996 | A |
5614549 | Greenwald et al. | Mar 1997 | A |
5650510 | Webb, II et al. | Jul 1997 | A |
5654466 | Stuk et al. | Aug 1997 | A |
5681964 | Ashton et al. | Oct 1997 | A |
5707984 | Tjoeng et al. | Jan 1998 | A |
5712400 | Leanna et al. | Jan 1998 | A |
5714148 | Burke et al. | Feb 1998 | A |
5847003 | Ptchelintsev et al. | Dec 1998 | A |
5880131 | Greenwald et al. | Mar 1999 | A |
5918568 | Gjerlov | Jul 1999 | A |
6110908 | Guthery | Aug 2000 | A |
Number | Date | Country |
---|---|---|
1 148 165 | Mar 1981 | CA |
0 357 495 | Mar 1990 | EP |
0 494 370 | Nov 1991 | EP |
0 540 751 | May 1992 | EP |
WO9622303 | Jan 1996 | WO |
WO0077020 | Jun 2000 | WO |
Number | Date | Country | |
---|---|---|---|
20040214784 A1 | Oct 2004 | US |
Number | Date | Country | |
---|---|---|---|
60132803 | May 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09565079 | May 2000 | US |
Child | 10851096 | US |